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Abstract
Colon cancer comprises a small population of cancer initiating stem cells (CIC) that is responsible for tumor maintenance
and resistance to anti-cancer therapies, possibly allowing for tumor recapitulation once treatment stops. Combinations of
immune-based therapies with chemotherapy and other anti-tumor agents may be of significant clinical benefit in the
treatment of colon cancer. However, cellular immune-based therapies have not been experimented yet in the population of
colon CICs. Here, we demonstrate that treatment with low concentrations of commonly used chemotherapeutic agents, 5-
fluorouracyl and doxorubicin, sensitize colon CICs to Vc9Vd2 T cell cytotoxicity. Vc9Vd2 T cell cytotoxicity was largely
mediated by TRAIL interaction with DR5, following NKG2D-dependent recognition of colon CIC targets. We conclude that
in vivo activation of Vc9Vd2 T cells or adoptive administration of ex-vivo expanded Vc9Vd2 T cells at suitable intervals after
chemotherapy may substantially increase anti-tumor activities and represent a novel strategy for colon cancer
immunotherapy.
Citation: Todaro M, Orlando V, Cicero G, Caccamo N, Meraviglia S, et al. (2013) Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vc9Vd2 T Cell-Mediated
Cytotoxicity. PLoS ONE 8(6): e65145. doi:10.1371/journal.pone.0065145
Editor: Jacques Zimmer, Centre de Recherche Public de la Sante´ (CRP-Sante´), Luxembourg
Received March 5, 2013; Accepted April 23, 2013; Published June 6, 2013
Copyright:  2013 Todaro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by grants from the Italian Ministry for Instruction, University and Research (contract no. 2008L57JXW to FD), the Italian
Ministry of Health (Progetto Ricerca Finalizzata 2007 ‘‘Stem cells in different pathological conditions: innovative therapeutical approches’’ to FD), Istituto Superiore
di Sanita` Oncoproteomic Project 2007-527/B/3A/3 (to GS and FD) and the University of Palermo. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors declare no financial or commercial conflict of interest. The corresponding author, Francesco Dieli, is an Academic Editor of
PLOS ONE. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: francesco.dieli@unipa.it
Introduction
In recent years, novel insights in cancer research have suggested
that the capacity to initiate and sustain tumor growth is a unique
characteristic of a small subset of cancer cells with stemness
properties within the tumor mass, called ‘‘cancer stem cells’’
(CSCs) or ‘‘cancer-initiating cells’’ (CICs) [1]. Chemotherapy
remains the primary treatment choice for many advanced cancers
and has cytotoxic anti-tumor activity through a range of
mechanisms. However, most cancers are resistant to current
therapies due to the slow-cycling CICs, the location of these cells
within hypoxic niches [2,3], and because the malignant cells have
the capacity to develop mechanisms to resist or escape the
cytotoxic effects of chemotherapy [4], which include up-regulation
of several ATP-binding cassette transporters, active DNA-repair
capacity and over-expression of anti-apoptotic molecules that
cause changes in the signalling pathways controlling proliferation,
differentiation and apoptosis [5].
Several studies have demonstrated that treatment of tumor cells
with chemotherapeutic drugs induces or increases their sensitivity
to cytotoxicity by NK or T lymphocytes; thus, combinations of
cellular immune-based therapies with chemotherapy and other
anti-tumor agents may be of significant clinical benefit in the
treatment of many forms of cancer [6].
cd T cells are of particular interest for use in such combined
therapies due to their potent anti-tumor cytotoxicity and the
relative ease of generation in vitro [7]. Human cd T cells can be
divided into two main populations based upon d chain expression
[8]: cd T cells expressing the Vd1 chain are most often found in
mucosal tissues, where they are involved in maintaining epithelial
tissue integrity in the face of damage, infection, or tumor
transformation, while cd T cells expressing the Vd2 chain paired
to the Vc9 chain (here and thereafter called Vc9Vd2 T cells)
predominate in the peripheral blood and secondary lymphoid
organs [9]. While the ligand(s) recognized by Vd1 cells remain
unknown, Vc9Vd2 T cells recognize non peptidic antigens by a
MHC-unrestricted mechanism, an important feature which
distinguishes them from ab T cells [9]. Specifically, Vc9Vd2 T
cells recognize phosphoantigens that are produced through the
isoprenoid biosynthesis pathways [10–12]. Phosphoantigens are
not stimulatory at physiologic levels, but transformed and infected
cells, produce increased levels of metabolic intermediates that are
able to activate Vc9Vd2 T cells [13–15]. Accordingly, Vc9Vd2 T
cells can also be activated, through an indirect mechanism, by
aminobisphosphonates, a class of drugs used to treat certain bone
diseases, that inhibit farnesyl pyrophosphate synthase, and cause
accumulation of endogenous upstream metabolites such as
isopentenylpyrophosphate (IPP) [16]. Vc9Vd2 T cells may indi-
rectly contribute to the immune defense against cancer cells, by
producing cytokines typical of Th1, Th2 or Th17 cells [17–19], or
cross-talking with dendritic cells [20], macrophages [21] and B
cells [22–24]. Additionally, Vc9Vd2 T cells perform direct potent
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cytotoxic activity toward cancer cells, which is mediated in much
the same manner as for CD8 T cells and NK cells, through
perforin/granzyme, Fas/FasL, TNF/TNF-R and TRAIL-
TRAIL-R pathways [10].
In this study, we have assessed the potential synergy of
combining chemotherapy and Vc9Vd2 T cell-mediated cytotox-
icity for anti-tumor therapy. Specifically, as colon CICs are
resistant to both chemotherapeutic drugs and to Vc9Vd2 T cell-
mediated cytotoxicity, we have determined whether chemotherapy
can be used to sensitize colon CIC targets to Vc9Vd2 T cell
cytotoxicity, based on three lines of evidence: (1) pioneering work
by Mattarollo and colleagues [25] has demonstrated high levels of
cytotoxicity against solid tumor-derived cell lines with combination
treatment utilizing Vc9Vd2 T cells and chemotherapeutic agents;
(2) IL-17-producing cd T cells play a decisive role in chemother-
apy-induced anti-cancer immune responses in the mouse [26]; (3)
treatment of colon CICs with the bisphosphonate zoledronate
enhances their sensitivity to Vc9Vd2 T cell killing [27].
We show here that chemotherapeutic drugs currently used for
treatment of colon cancer patients, 5-fluorouracyl and doxorubi-
cin, are capable to sensitize colon CICs to Vc9Vd2 T cell-
mediated killing and we demonstrate that the underlying
mechanisms involve NKG2D and TRAIL.
Results
Resistance of Colon CICs to Chemotherapy
We have previously reported that colon cancer comprises a vast
majority of differentiated cells and a small population of CICs that
are responsible for tumor initiation and maintenance [28]. For this
study purposes, we purified and propagated colon cancer spheres
from surgical fragments of 5 patients with colon carcinoma. These
cancer sphere lines were identified through the expression of
CD133 and the epithelial specific antigen ESA, displayed
adherence to the culture dishes in the presence of serum and
subsequently differentiated into large, polygonal colon cells
expressing colon epithelial markers, such as villin, suggesting that
colon cancer spheres maintained the ability to in vitro differentiate
in enterocyte-like cells. Most importantly, when injected subcuta-
neously into NOD/SCID mice, a low number of colon cancer
spheres, but not sphere-derived differentiated cells, retained the
capacity to form a tumor that closely resembled the human
original tumor (Supporting Figure S1).
CICs are characterized by high resistance to drugs and general
toxins which target rapidly proliferating cells and spare the slow
dividing cells, due to an up-regulation of several ATP-binding
cassette transporters, active DNA-repair capacity, over-expression
of anti-apoptotic molecules that cause changes in the signalling
pathways controlling proliferation, differentiation and apoptosis
[5]. Accordingly, exposure of 5 different colon CIC lines (CIC#1
to CIC#5) to 5-FU (2.5 and 25 mg/ml) (Figure 1A) or DXR
(0.025 and 0.25 mM) (Figure 1B) for 24–72 hrs had virtually no
significant cytotoxic effect, as determined by PI staining. Highest
doses of 5-FU (250 mg/ml) and DXR (2.5 mM) caused low, yet
detectable cytotoxicity of CIC lines ranging from 1565% to
2366% (mean 6 SD). Conversely, 5-FU and DXR were fully
capable of killing 3 differentiated colon cancer cell lines DLD-1,
SW620 and SW403, and 2 differentiated cell lines (CDC#3 and
CDC#4) obtained from two patients (P#3 and P#4) where form
the CICs lines were also obtained, with a dose-dependent increase
in cytotoxicity up to 85%. The viability of untreated cells was all
over 90% (Figures 1A and B).
Chemotherapy Sensitizes Colon CICs to Vc9Vd2 T Cell
Cytotoxicity
In analogy to their resistance to chemotherapy, the five tested
colon CIC lines, were also resistant to Vc9Vd2 T cell-mediated
cytotoxicity, even when an E:T ratio of 50:1 was used (Figure 2A).
The poor cytotoxic activity against colon CICs was not an intrinsic
feature of the Vc9Vd2 T cells, because the differentiated colon
cancer cell lines DLD-1, SW620, SW403, CDC#3 and
CDC#4 were efficiently killed by two Vc9Vd2 T cell lines
COLD2-1 and COLD2-2 obtained from two different colon
cancer patients (P#3 and P#4) (Figure 2A), as well as Vc9Vd2 T
cell lines obtained from healthy subjects (data not shown). As a
control, all the tested Vc9Vd2 T cell lines failed to kill the normal
colon cell line CCL-241 (Figure 2A).
In previous studies, we have demonstrated that zoledronate
sensitizes colon cancer CICs to Vc9Vd2 T cell cytotoxicity [27].
The capability of Vc9Vd2 T cells to kill colon cancer CICs was
then assessed after treatment of the targets with chemotherapy.
Representative results obtained with three different CIC lines
(CIC#2, CIC#4 and CIC#5) are shown in Figure 2B.
Vc9Vd2 T cell cytotoxicity was enhanced in all cases by pre-
treatment of target CICs with chemotherapy. In detail, almost
complete lysis of CIC lines resulted from the combination of the
highest doses of 5-FU (250 mg/ml) or DXR (2.5 mM) and
Vc9Vd2 T cells, with cell death percentages over 90% at an
E:T ratio of 20:1. Treatment of targets with lower doses
chemotherapy (2.5 and 25 mg/ml 5-FU and 0.025 and 0.25 mM
DXR) resulted in enhanced killing of CIC lines by Vc9Vd2 T
cells, indicating that chemotherapy and Vc9Vd2 T cells have
additive activity even when used at suboptimal doses.
Chemotherapy Upregulates DR5 (TRAIL-R2) Death
Receptor Expression on CICs
To decipher the molecular mechanisms behind chemotherapy-
mediated sensitization of CICs to Vc9Vd2 T cells cytotoxicity, we
focused on expression of mRNA encoding for molecules known to
be ligands for key activating receptors on Vc9Vd2 T cells and
death receptors, before and after exposure of CICs to chemother-
apy agents. As shown in Figure 3, all of these molecules were
constitutively expressed in CICs, although expression consistently
varied amongst different CIC lines; however, no major differences
were observed in all tested CIC lines for HLA-class I, ICAM-1,
CD155, CD112, MICA/B and ULPBP1–4 expression before and
after exposure to chemotherapy agents.
Expression of Fas (CD95), TNF-R1, DR4 (TRAIL-R1) and
DR5 (TRAIL-R2) death receptors was increased in the majority of
CIC lines following exposure to chemotherapeutic agents
(Figure 3), but increased expression of Fas, TNF-R1 and DR4
did not attain statistical significance. The greatest and significant
increase was only observed for DR5 expression after exposure of
CICs to 5-FU and, although at a lesser extent, DXR (Figure 3).
Upregulation of DR5 following 48 hrs exposure of colon CICs to
chemotherapy was confirmed by flow cytometry upon staining
with specific mAb (Figure 4).
Killing of Chemotherapy-treated CICs by Vc9Vd2 T Cells
is Mediated by NKG2D and TRAIL
Vc9Vd2 T cells exploit different pathways for killing of tumor
cells that rely on secretion of proinflammatory cytokines and
proapoptotic molecules or on cell contact-dependent lysis through
NK-like or TCR-dependent interactions [9]. We assessed the
mechanisms responsible for killing of chemotherapy-sensitized
CICs by Vc9Vd2 T cells, by individually blocking TCR or
Chemotherapy Potentiates cd T Cell Cytotoxicity
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NKG2D receptors. Cytotoxicity of chemotherapy-pretreated
colon CIC lines by two different Vc9Vd2 T cell lines was
significantly inhibited by anti-NKG2D mAb, while the
Vc9Vd2 TCR seems to play a minor role as indicated by the
failure of anti-CD3 and anti-pan cd TCR mAbs to inhibit
cytotoxicity (Figure 5). In addition, Vc9Vd2 T cell killing of
chemotherapy-sensitized targets was assessed in the presence of
mevastatin, which inhibits 3-hydroxy-3-methylglutaryl-CoA and
prevents zoledronate-mediated accumulation of endogenous
phosphoantigens as IPP. Mevastatin failed to inhibit killing of all
tested chemotherapy-pretreated colon CIC lines by two different
allogeneic Vc9Vd2 T cell lines (Figure 5), thus indicating that
chemotherapy-induced sensitization of CICs to Vc9Vd2 T cell
cytotoxicity does not rely on production of mevalonate metabo-
lites.
To further elucidate the mechanisms of killing of chemother-
apy-sensitized colon CICs by Vc9Vd2 T cells, we individually
inhibited the granule exocytosis, TNF-a-, TRAIL-, and FasL-
mediated pathways. Killing-inhibition experiments revealed that
Vc9Vd2 T cell cytotoxicity of chemotherapy-pretreated colon
CIC targets was significantly inhibited by anti-DR5 mAb, whereas
mAbs against DR4, TNF-a, and FasL, or treatment with CMA to
block the granule-exocytosis pathway, all failed to inhibit.
Figure 6 shows representative data with two Vc9Vd2 T cell
lines and the two colon CIC lines, CIC#2 and CIC#4.
Discussion
It is now emerging that cancer is generated by a population of
cells displaying stemness features, named cancer stem cells or
cancer-initiating cells (CICs) [1,2]. These cells, which contribute
only to a minor fraction of the total tumor mass, undergo long-
term expansion with retention of their ability to reproduce the
original tumor phenotype, thus providing evidence for self-renewal
and tumor-initiating capacity [1,2]. The CIC population is more
resistant than differentiated primary cells to conventional chemo-
therapy and radiotherapy and to putative innovative therapies
such as those based on the use of TRAIL. This refractoriness has
been attributed to the fact that CICs express multidrug resistance
genes including high levels of anti-apoptotic proteins and ABC
(ATP Binding Cassette) transporters which pump out the drugs,
but also to the fact that chemotherapy targets dividing cells and
consequently fails to kill the slow-cycling CICs [3–5].
Data from recent clinical studies have suggested that combining
chemotherapy with immunotherapy has survival benefits than
chemotherapy alone [6,29], as outlined for example by the
combination of chemotherapy and monoclonal antibodies [30–
32]. Moreover, it is known that chemotherapeutic drugs can
sensitize tumor cells to cytotoxicity mediated by CD8, NKT or
Vc9Vd2 T cells [33] thorugh several different mechanisms [34].
However, we recently found that colon CICs are resistant to
Vc9Vd2 T cell cytotoxicity, unless they are sensitized with
zoledronate [35]: similarly, we have now tested the possibility
Figure 1. Cell cytotoxicity following treatment with 5-FU (A) or DXR (B). Colon CICs, differentiated colon cancer cell lines DLD-1, SW620,
SW403, CDC#3 and CDC#4 were treated with different concentrations of 5-FU or DXR for 48 hrs. Cytotoxicity (% 6 SD) was determined by the
degree of reduction of viable cells with the ability to retain CFSE and exclude PI (CFSEhigh PI2). Shown is a representative experiment out of three.
doi:10.1371/journal.pone.0065145.g001
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that chemotherapeutic drugs currently used in the treatment of
colon cancer might also sensitize colon CICs to Vc9Vd2 T cell
killing.
Initial testing of cytotoxicity revealed that in analogy with our
previously reported results [27], many colon CIC lines were
resistant to the cytotoxic activity of Vc9Vd2 T cells, but
pretreatment with low, sublethal concentrations of chemothera-
peutic drugs 5-FU and DXR sensitizes CIC targets to Vc9Vd2 T
cell killing, resulting in additive cytotoxicity activity.
Vc9Vd2 T cells interact with and kill tumor targets thorugh
several different mechanisms including granule exocytosis, death
receptor/ligands interactions with TNF, TRAIL and FasL, and
TCR- or NKG2D-mediated recognition of phosphoantigens or
stress-inducible molecules, respectively. All tested colon CIC lines
constitutively expressed mRNA encoding for HLA-class I, ICAM-
1, CD155, CD112, MICA/B, ULPBP1-4, Fas (CD95), TNF-R1,
DR4 (TRAIL-R1) and DR5 (TRAIL-R2) molecules on their
surface, but expression of all these molecules did not render CICs
sensitive to Vc9Vd2 T cell killing. However, exposure of colon
CICs to 5-FU and, although at a lesser extent DXR, significantly
increased DR5 expression.
Several previously published reports in the literature have
demonstrated that many chemotherapeutic drugs, including 5-FU
and DXR, upregulate DR5 expression on tumor cell lines of
distinct tissue origin [36–42]. However, this effect has been
reported on differentiated cancer cells, while, to our knowledge,
there is no evidence of similar DR5 upregulation on CICs.
Whether or not chemotherapy-induced DR5 upregulation is
restricted to colon CICs or is a general phenomenon observed on
other CICs is actually under study.
Nonetheless, we found that Vc9Vd2 T cells exploited different
mechanisms to kill CIC targets, which were strictly dependent on
the way of target CICs sensitization. Regardless of whether
chemotherapeutic drugs or zoledronate were used to sensitize
Figure 2. Chemotherapy sensitizes resistant colon CICs to Vc9Vd2 cell-mediated cytotoxicity. (A) Cytotoxicity percentage of 2 different
to Vc9Vd2 T cell lines, COLD2-1 and COLD2-2 obtained from 2 patients affected by colon cancer, against colon cancer sphere cells from 5 different
patients (CIC#1 to CIC#5), differentiated colon cancer cell lines DLD-1, SW620, SW403, CDC#3 and CDC#4, and the normal colon cell line CCL-241,
at an E:T ratio of 50:1. (B) Three different target colon CICs (CIC#2, CIC#4 and CIC#5) treated with or without either 5-FU (2.5 to 250 mg/ml) or DXR
(0.025 to 2.5 mM) for 48 hrs were tested for their sensitivity to 2 different to Vc9Vd2 T cell lines, COLD2-1 and COLD2-2 obtained from 2 patients
affected by colon cancer and used at an E:T ratio of 20:1. Results indicate cytotoxicity of tumor targets following 6 hrs co-culture with Vc9Vd2 T cell
lines. Data are mean percentage 6 SD of 5 different experiments, each carried out in triplicate.
doi:10.1371/journal.pone.0065145.g002
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CICs, Vc9Vd2 T cells killing of these targets was TCR- or
NKG2D-mediated: consistent with our previous report [27]
chemotherapy-sensitized colon CICs were killed following
NKG2D-mediated recognition and TRAIL/DR5 interaction,
while both mechanisms were dispensable to the cytotoxicity of
zoledronate-sensitized colon CICs, which were almost exclusively
killed by TCR-mediated interaction and the perforin/granzyme
pathway.
Previous studies have highlighted the importance of NKG2D-
MICA/B interactions for tumour cell recognition and effective
cytotoxic activity by Vc9Vd2 T cells [35–44]. The difference
between NKG2D-mediated recognition of chemotherapy-sensi-
tized colon CICs and TCR-mediated recognition of zoledronate-
sensitized CIC targets cannot be explained differential expression
of MICA/B or ULBPs since neither 5-FU nor DXR changed
constitutive expression levels of these molecules. It is likely that
phosphoantigens production/expression by colon CICs is very
low, below the threshold required for efficient recognition by the
reactive Vc9Vd2 TCR, hence target recognition only occurs
through NKG2D: the finding that colon CICs become sensitive to
Vc9Vd2 T cell cytotoxicity upon exposure to zoledronate [27],
which enhances phosphoantigen accumulation and production,
supports this possibility.
We conclude that in vivo activation of Vc9Vd2 T cells or
adoptive transfer of ex vivo-activated Vc9Vd2 T cells, together with
or soon after administration of certain chemotherapeutic drugs
may substantially increase their anti-tumor effects. Additional
clinical studies are thus needed to assess the efficacy of this
combinatory therapy, possibly including the novel cd T cell-based
immunotherapeutic approach that ex-vivo expansion of polyclonal
cd T cells followed by introduction of a CD19-specific chimeric
antigen receptor render them bispecific and more efficient in
killing of CD19+ tumor cell lines in vitro and in xenografts [45].
Materials and Methods
Peripheral Blood and Colon Cancer Samples
Human peripheral blood mononuclear cells (PBMC) and colon
cancer tissues were obtained in accordance with the ethical
standards of the institutional committee of human experimenta-
tion from patients undergoing a colon resection for colon
adenocarcinoma. Histological diagnosis was based on microscopic
features of carcinoma cells determining the histological type and
grade. PBMC were isolated from colon cancer patients by density
gradient centrifugation using Ficoll-Hypaque (Pharmacia Biotech,
Uppsala, Sweden) and were cryopreserved in 80% RPMI 1640
(Life Technologies, Monza, Italy), 10% DMSO (Sigma, St. Louis,
MO) and 10% heat-inactivated fetal calf serum (FCS, Life
Technologies).
According to Italian rules (Article 13 of Legislative Decree
no. 196/03), this study did not require authorisation by the local
ethical committee. The study was performed in accordance to the
principles of the Helsinki declaration and all individuals gave
written informed consent to participate.
Purification and Culture of CICs
Cancer tissues were extensively washed in saline buffer
containing antibiotics and incubated overnight in DMEM/F12
(Life Technologies) containing penicillin (500 IU/ml), streptomy-
cin (500 mg/ml) and amphotericin B (1.25 mg/ml) (Life Technol-
Figure 3. Colon CICs constitutively express molecules involved in by Vc9Vd2 T cell-mediated cytotoxicity: effect of chemotherapy.
RT-PCR of the expression of mRNA encoding for different surface molecules in colon CICs treated with or without either 5-FU (25 mg/ml) or DXR
(0.25 mM) for 48 hrs. Data represent the mean values 6 SD of 4 separate experiments, each performed with colon cancer spheres from 5 different
patients (CIC#1 to CIC#5).
doi:10.1371/journal.pone.0065145.g003
Figure 4. Chemotherapy upregulates DR5 expression on coloc
CICs. Colon CICs were treated with medium, 5-FU (25 mg/ml) or DXR
(0.25 mM) for 48 hrs, washed extensively and stained with anti-DR5
mAb. Flow cytometry histograms show DR5. Mean fluorescence
intensity (MFI) for DR5 staining is indicated in the upper right corner
of each panel. Dotted lines represent isotype control mAb, while grey
filled histogram represent anti-DR5 mAb.
doi:10.1371/journal.pone.0065145.g004
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ogies). Enzymatic digestion was performed using collagenase (Life
Technologies, 1.5 mg/ml) and hyaluronidase (Sigma, 20 mg/ml)
in DMEM containing antibiotics/antimycotics for 1 hour. Recov-
ered cells were then cultured in serum-free medium (DMEM/F12)
supplemented with 6 mg/ml Glucose, 1 mg/ml NaHCO3, 5 mM
HEPES, 2 mM L-Glutamine, 4 mg/ml Heparin, 4 mg/ml BSA,
10 ng/ml bFGF, 20 ng/ml EGF, 100 mg/ml apotrasferrin,
25 mg/ml insulin, 9,6 mg/ml putrescin, 30 nM sodium selenite
anhydrous and 20 nM progesterone (Sigma) to a final concentra-
tion of 36105 cells/ml. These culture conditions select for
immature tumor cells that slowly proliferate, giving rise, within
2–3 months, to tumor cell aggregates, called ‘‘spheres’’. Sphere-
forming cells can be propagated by enzymatic dissociation of
spheres (3 mM EDTA, 50 nM DTT in PBS), followed by re-
plating of single cells and residual small cell aggregates in fresh
serum-free medium [28,46,47].
Tumorigenicity was evaluated by subcutaneous implantation of
either disaggregated colon cancer sphere cells or sphere-derived
differentiated cells [27]. Differentiated colon cancer cells lines
DLD-1, SW620 and SW403 (American Type Culture Collection)
were obtained from Dr. Ruggero De Maria (‘‘Regina Elena’’
National Cancer Institute, Rome, Italy) and were maintained in
DMEM containing antibiotics and 10% FCS. All cell cultures
were carried out at 37uC in a 5% CO2 humidified incubator.
Anti-tumor Agents, Antibodies and Reagents
The chemotherapeutic agents 5-fluorourcil (5-FU) and doxoru-
bicin (DXR) were obtained from Sigma, through the pharmacy of
the University Hospital. Drugs were diluted in DMSO and diluted
to the required concentrations in PBS prior to use.
The following unconjugated, FITC-, PE-, PE-Cy5- or APC-
conjugated monoclonal antibodies (mAbs) were used: anti-TCR
Vd2 (B6, BD Biosciences, San Jose´, CA), anti-NKG2D (1D11,
eBioscience, San Diego, CA), anti-CD95L (2C101,Vinci Biochem,
Firenze, Italy), anti-MICA/B (6D4, BD Biosciences).
Additionally, the following purified mAbs were also used: anti-
CD3 (blocking, MEM-57), anti-HLA Class I monomorphic
(MEM-147) from Prof. Vaclav Horejsi (Institute of Molecular
Figure 5. Modulation of the cytotoxic activity of Vc9Vd2 T cells by blocking the TCR or NKG2D interactions. The Vc9Vd2 T cell line
COLD2-1 was cultured with two chemotherapy-treated colon CICs (CIC#3 and CIC#5) at an E:T ratio of 20:1, in the presence of blocking antibodies to
the cd TCR, CD3, NKG2D, or in the presence of mevastatin. Specific cytotoxicity levels achieved by the Vc9Vd2 T cell line COLD2-1 were 65611 for
CIC#3 and 7169 for CIC#5. Data are mean 6 SD of two experiments carried out in triplicate. Percent inhibition with anti-NKG2D mAb was
significantly different than values in all other groups (*p,0.001).
doi:10.1371/journal.pone.0065145.g005
Figure 6. Modulation of the cytotoxic activity of Vc9Vd2 T cells by blocking death receptors interactions. The Vc9Vd2 T cell line
COLD2-1 was cultured with two chemotherapy-treated colon CICs (CIC#3 and CIC#5) at an E:T ratio of 20:1, in the presence of blocking antibodies to
TNF-a, FasL (CD95L), TRAIL receptors R1 (DR4) or R2 (DR5), or concanamycin A (CMA). Specific cytotoxicity levels achieved by the Vc9Vd2 T cell line
COLD2-1 were 6167 for CIC#3 and 65612 for CIC#5. Data are mean 6 SD of experiments carried out in triplicate. Percent inhibition with anti-DR5
and anti-TRAIL mAbs were significantly different than values in all other groups (*p,0.001).
doi:10.1371/journal.pone.0065145.g006
Chemotherapy Potentiates cd T Cell Cytotoxicity
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Genetics, Prague, Czech republic), anti-TCR pan cd (IMMU510,
a gift of Dr. Marc Bonneville, Institut de Biologie, Nantes, France),
anti-TNF-a (Infliximab, a gift of Prof. Giovanni Triolo, Diparti-
mento Biomedico di Medicina Interna e Specialistica, Universita`
di Palermo, Palermo, Italy), anti-TRAIL receptors TRAIL-
R1(DR4), TRAIL-R2 (DR5), TRAIL-R3 (LIT, DcR1) and
TRAIL-R4 (TRUNDD, DcR2) all provided by Dr. Henning
Walczak (Tumor Immunology Unit, Division of Medicine,
Imperial College, London, UK).
Concanamycin A (CMA) and mevastatin were purchased from
Sigma, while zoledronate was from Novartis Pharma, Basel,
Switzerland.
Generation of Polyclonal Vc9Vd2 T Cell Lines
Polyclonal Vc9Vd2 T cell lines were generated by first
enriching PBMC using a cd T cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany), followed by sorting single
Vc9Vd2 T cells through a FACSAria (BD Biosciences) with
specific mAbs. Cells (26103) were then cultured into each well of
round-bottom, 96-well plates containing 26104 irradiated (40 Gy)
allogeneic PBMC, 26103 irradiated (70 Gy) EBV-transformed
allogeneic B cells, 0.5 mg/ml PHA (Sigma), and 200 U/ml
recombinant interleukin 2 (Proleukin, Novartis Pharma). Growing
lines were expanded in 200 U/ml IL-2 and restimulated every 2
weeks. Usually, cells were collected after 4–6 weeks of culture to be
used for functional assays in vitro.
Cytotoxic Assay
Target colon CIC (105 cellsml) were pre-treated with 5-FU (2.5–
250 mg/ml), DXR (0.025–2.5 mM) or zoledronate (0.5 mM) for 24,
48 or 72 hrs. Cells were extensively washed in PBS and stained
with CFSE (Merck, Milano, Italy) as follows: 50 ml of CFSE were
added to 1 ml of target sphere cell suspension (56105 cells/ml) in
PBS to obtain the final concentration of 2.5 mM CFSE. The cells
were incubated for 10 minutes at 37uC and gently mixed every
5 min. At the end of incubation, 1 ml of FBS was added to the cell
suspension to stop the staining reaction and the cells were
centrifuged at 600 g for 5 min at room temperature, washed twice
with cold PBS and resuspended in serum-free medium.
Vc9Vd2 T cell lines were resuspended at the final concentra-
tions of 106 and 2.56106 cells/ml, were added to CFSE-stained
target colon CICs (16105) and co-cultures were maintained for
6 hrs a 37uC in presence of 5% of CO2. At the end of the
incubation period, the cells were washed with PBS and stained
with 20 ml of Propidium Iodide (PI, Sigma, 1 mg/ml) for 10–
15 min in ice. Finally 100 ml of cold PBS were added before
acquisition on a FACSCalibur cytometer (BD Biosciences). The
calculation of cytolytic activity was based on the degree of
reduction of viable target cells with the ability to retain CFSE and
exclude PI (CFSEhigh PI2), according to reference [27].
Blocking agents were used to evaluate the mechanisms of
Vc9Vd2 T cell-mediated cytotoxicity of colon CICs. To evaluate
the contribution of mevalonate metabolites tumor target cells were
treated with mevastatin (25 mM for 2 h) a selective upstream
inhibitor of the mevalonate pathway. After this incubation period,
target cells were washed, and Vc9Vd2 T cells added in the
presence of 25 mM mevastatin, to maintain a constant concentra-
tion of this drug during incubation because its effect is rapidly
reversible [27]. To inhibit perforin-mediated cytotoxicity,
Vc9Vd2 T cells were incubated with concanamycin A (CMA,
15 nM) for 30 min at 37uC before co-culture with target CICs,
without further washing [27]. To block the relevant cytotoxic
pathways, specific or isotype-control mAbs were used at 10 mg/ml
final concentration just before co-incubation assay [27].
Real-time Quantitative RT-PCR
Total RNA was extracted with the ABI PRISM 6100 Nucleic
Acid PrepStation (Applied Biosystems through Life Technologies)
according to the manufacturer’s instructions. Random hexamers
and an MMLV Reverse Transcriptase kit (Stratagene, La Jolla,
CA) were used for cDNA synthesis. Transcripts were quantified by
real-time quantitative PCR on an ABI PRISM 7700 Sequence
Detector (Applied Biosystems) with Applied Biosystems prede-
signed TaqMan Gene Expression Assays and reagents according
to the manufacturer’ s instructions. The following probes were
used (identified by Applied Biosystems assay identification
number): HLA-A, Hs01058806_g1; HLA-B, Hs00818803_g1;
HLA-C, Hs00740298_g1; ICAM-1, Mm00516023_m1; CD155,
Hs00197846_m1; CD112, Hs01071562_m1; MICA,
Hs00741286_m1; MICB, Hs00792952_m1; ULBP-1,
Mm01180648_m1; ULBP-2, Hs00607609_mH; ULBP-3,
Hs00225909_m1; Fas (CD95), Hs00236330_m1; TNF-R1,
Mm00441883_g1; DR4 (TRAIL-R1), Hs00269492_m1; DR5
(TRAIL-R2), Hs00366278_m1. For each sample, mRNA abun-
dance was normalized to the amount of 18S rRNA.
Statistics
The two-tailed Student’s t test was used to compare significance
of differences between groups. All values are expressed as mean 6
standard deviation (SD).
Supporting Information
Figure S1 A low number of colon CIC spheres retain the
capacity to form a tumor when injected s.c. into
immunodeficient mice. Subcutaneous tumor growth in
NOD/SCID mice 10 weeks after injection of 2000 disaggregated
cells from colon cancer spheres. One representative experiment of
two performed with cells from different donors is shown.
(TIF)
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